Litigation Details for Allergan, Inc. v. Sandoz, Inc. (Fed. Cir. 2015)

Allergan, Inc. v. Sandoz, Inc. (Fed. Cir. 2015)

Docket		Date Filed	2015-10-19
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	4,599,353; 6,403,649; 7,351,404; 7,388,029; 8,038,988; 8,101,161; 8,263,054; 8,906,962; 8,926,953
Link to Docket	External link to docket

Details for Allergan, Inc. v. Sandoz, Inc. (Fed. Cir. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-10-19				External link to document
2015-10-19	38		in Ophthalmology, 1993, 44-50, 4(11). 6,403,649 Bl 612002 Woodward …However, the ’953 patent is related to U.S. Patent No. 7,351,404, and the ’404 patent was the subject …assert newly issued patent claims that are patentably distinct from its earlier patents. Allergan’s Latisse…different asserted patent (U.S. Patent No. 7,388,029, which is unrelated to the patent-in-suit here) and…three additional patents that were continuations of the ’404 patent, namely U.S. Patent Nos. 8,038,988;	External link to document

Allergan, Inc. v. Sandoz, Inc. 16-1085: Litigation Summary and Patent Analysis

Last updated: August 15, 2026

Allergan, Inc. v. Sandoz, Inc., No. 16-1085, was a Federal Circuit appeal involving Sandoz's abbreviated new drug application for a generic version of Lumigan 0.01%, Allergan's bimatoprost ophthalmic solution for glaucoma and ocular hypertension. The dispute concerned Allergan's formulation patents, claim construction, infringement, and validity under the Hatch-Waxman framework. The Federal Circuit affirmed the district court's judgment for Allergan, preserving patent protection against the Sandoz ANDA product.[1]

What drug and patents were at issue in Allergan v. Sandoz 16-1085?

The litigation concerned Lumigan 0.01%, an ophthalmic formulation containing bimatoprost. Bimatoprost is a prostaglandin analog used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The principal patents were:

Patent	Subject matter	Patent holder	Litigation role
U.S. Patent No. 7,851,504	Bimatoprost ophthalmic formulation containing approximately 0.01% bimatoprost	Allergan	Asserted against Sandoz's ANDA
U.S. Patent No. 8,629,111	Related bimatoprost ophthalmic formulation claims	Allergan	Asserted in the Lumigan patent litigation
Related continuation patents	Formulation and ophthalmic-use protection	Allergan and affiliates	Relevant to the broader generic-entry campaign

The asserted claims focused on the concentration and composition of the ophthalmic solution, including the use of approximately 0.01% bimatoprost. The patents were formulation patents rather than patents covering bimatoprost as a chemical entity.

What was the procedural history of the case?

Allergan sued Sandoz after receiving a Paragraph IV certification stating that Sandoz's proposed generic product would not infringe the asserted patents or that the patents were invalid. The lawsuit triggered the Hatch-Waxman 30-month stay of FDA approval for the ANDA.[2]

The litigation proceeded in the U.S. District Court for the Eastern District of Texas. The district court addressed claim construction, infringement, obviousness, and related validity issues. The case reached the Federal Circuit under docket No. 16-1085.

The Federal Circuit's decision maintained the district court's judgment in Allergan's favor. Sandoz therefore remained subject to the statutory stay and could not obtain FDA approval for the ANDA product while the relevant patent barriers remained effective.

What did the Federal Circuit decide?

The Federal Circuit upheld Allergan's asserted patent rights against Sandoz. The decision was significant for three reasons.

First, the court treated the claimed bimatoprost concentration as a limitation that could be applied to Sandoz's proposed product. The word "about" did not eliminate the concentration requirement. It provided a range of reasonable variation around the stated concentration.

Second, the court rejected Sandoz's invalidity arguments. The record supported the district court's conclusion that the claimed 0.01% formulation was not rendered obvious by the prior art. The lower concentration had commercial and clinical significance because it reduced the incidence of hyperemia, or eye redness, while maintaining intraocular-pressure reduction.

Third, the decision preserved Allergan's ability to use formulation patents to delay generic entry even though bimatoprost itself was not protected by a composition-of-matter patent. The case illustrates how an innovator can extend commercial protection through dosage-form and concentration claims.

How did claim construction affect the infringement dispute?

The central construction issue involved the scope of the claimed bimatoprost concentration and related formulation limitations.

A claim using "about 0.01%" does not necessarily cover every concentration that is close to 0.01%. Courts assess the term in view of:

• The patent specification.
• The prosecution history.
• The relevant technical field.
• The precision used elsewhere in the claims.
• The purpose of the claimed range.

Allergan's formulation patents described a low-concentration bimatoprost product designed to retain efficacy while improving tolerability. The Federal Circuit accepted a construction that gave effect to the concentration limitation and permitted comparison with the composition disclosed in Sandoz's ANDA.

For ANDA litigation, the court generally compares the patent claims with the product described in the ANDA, not with later commercial conduct. The ANDA's formulation, manufacturing specifications, and proposed labeling therefore determined the infringement analysis.[3]

Why did the court reject Sandoz's obviousness challenge?

Sandoz argued that a person of ordinary skill could have arrived at the claimed 0.01% formulation by adjusting known bimatoprost concentrations. The Federal Circuit did not accept a simple concentration-reduction theory.

The relevant analysis considered whether the prior art supplied a reason to select the claimed concentration with a reasonable expectation of success. The court also considered evidence that the lower concentration delivered a useful balance between efficacy and side-effect reduction.

The patentability issue was not whether a skilled formulator could physically prepare a 0.01% solution. It was whether the prior art would have made the claimed formulation an obvious choice, supported by an expectation that the formulation would preserve the desired therapeutic effect.

The court's approach is commercially relevant. In ophthalmic products, a change in concentration can affect:

• Intraocular-pressure reduction.
• Hyperemia and other local adverse effects.
• Preservative exposure.
• Stability.
• Drop volume and dosing performance.
• Patient adherence.

A generic applicant challenging a formulation patent must address the full technical rationale for the claimed concentration, not merely demonstrate that the formulation could be produced.

What was the Hatch-Waxman and Paragraph IV significance?

Sandoz's ANDA litigation was based on a Paragraph IV certification. Under 21 U.S.C. § 355(j)(2)(A)(vii)(IV), an ANDA applicant may assert that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.[2]

The first Paragraph IV notice can create 180-day shared or competitive exclusivity for the first qualifying generic applicant under the statutory framework. The record in this case does not establish that Sandoz obtained a first-filer 180-day exclusivity position for Lumigan 0.01%.

The practical effects of the litigation were:

1. Allergan obtained a patent-based barrier against Sandoz's proposed product.
2. FDA approval of the ANDA was delayed during the statutory stay.
3. Other generic applicants faced the same listed-patent issues unless they adopted a different certification or prevailed in separate litigation.
4. The decision increased the value of non-chemical formulation patents in the Lumigan product line.

What was the Orange Book status of Lumigan?

Lumigan was listed in the FDA Orange Book with patents directed to the product's formulation and related characteristics. The relevant patents were not classic active-ingredient patents covering bimatoprost as a molecule. They were product patents covering the marketed ophthalmic formulation.[4]

Orange Book listing status matters because an FDA-listed patent can trigger a Paragraph IV dispute and the 30-month stay. An Orange Book patent does not establish validity or infringement. Those issues remain for the courts.

For Lumigan, the commercial protection strategy relied on a combination of:

• The original product approval.
• Listed formulation patents.
• Patent-term adjustment or continuation protection where available.
• Hatch-Waxman litigation against ANDA applicants.
• Regulatory exclusivity separate from patent rights.

The precise FDA approval and patent-expiration dates must be evaluated patent by patent because continuation patents can have different expiration calculations, while patent-term adjustment and pediatric exclusivity can alter effective market protection.[4]

When did Lumigan lose exclusivity?

Lumigan's exclusivity did not end on a single date. The product was subject to several overlapping forms of protection.

Regulatory exclusivity

Regulatory exclusivity is tied to the FDA approval pathway and the status of the original application. It is separate from patent protection and generally expires before the last enforceable formulation patent.

Patent exclusivity

The key commercial constraint was the expiration or successful invalidation of the listed formulation patents. A patent's nominal expiration date is based principally on the earliest effective nonprovisional filing date in the patent family, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and pediatric exclusivity.[5]

Generic entry

A generic could enter before the latest patent expiration only if:

• The generic applicant prevailed in litigation.
• Allergan dismissed or settled the claims.
• The applicant obtained a noninfringement judgment.
• The listed patents were removed or no longer blocked FDA approval.
• The generic entered under a legally permissible carve-out or other regulatory route.

The 16-1085 decision delayed Sandoz's ANDA pathway because the Federal Circuit upheld Allergan's patent position.

Did the case involve method-of-use patents?

The principal dispute in No. 16-1085 concerned formulation protection rather than a pure method-of-use patent. Lumigan's principal commercial value was tied to the bimatoprost ophthalmic product and its concentration.

Method-of-use patents can create a separate Orange Book and litigation strategy when the label includes a patented indication or dosing method. They can also support a section viii “skinny label” strategy if the generic applicant removes the patented use from its labeling and the remaining label supports a noninfringing use.[2]

That strategy was less central here than the formulation claims. Sandoz's product was evaluated against the composition described in its ANDA.

How strong was Allergan's patent estate?

The estate was commercially strong against the specific Sandoz ANDA because the Federal Circuit affirmed the lower court's judgment. Its strength had four dimensions.

Technical strength

The claims targeted a defined ophthalmic concentration and formulation. Such claims can be difficult to design around without changing the product's clinical or commercial profile.

Litigation strength

Allergan prevailed at the district court and on appeal. That record materially increased the risk for other ANDA applicants pursuing the same product profile.

Regulatory strength

The patents were listed in the Orange Book, enabling Paragraph IV litigation and the statutory approval stay.

Residual vulnerability

Formulation patents remain more vulnerable than a valid composition-of-matter patent if:

• Prior art discloses the same excipients and concentration range.
• The specification does not adequately support the claimed range.
• The claims are narrowly drafted.
• A generic product falls outside the claim construction.
• The formulation can be redesigned without losing bioequivalence or commercial acceptability.

The appellate victory strengthened the estate but did not make every Allergan patent covering bimatoprost immune from later challenges.

Which companies challenged Allergan's Lumigan patents?

Sandoz was one of several generic applicants involved in challenges to Allergan's ophthalmic-product patents. Generic competition for major ophthalmic products commonly included companies such as:

• Sandoz.
• Apotex.
• Teva.
• Mylan.
• Watson or related Actavis entities.
• Other ANDA applicants depending on the specific product and patent set.

The litigation outcome for one applicant did not automatically resolve every claim against every other applicant. Each ANDA could differ in concentration, excipients, preservative system, manufacturing process, labeling, or certification position.

What generic launch risks existed after the decision?

The decision created a high-risk environment for a generic with the same 0.01% bimatoprost formulation.

Generic strategy	Risk profile
Same concentration and formulation	High infringement risk
Different concentration	Potential noninfringement, but clinical and regulatory risk
Different excipient system	Possible design-around, subject to claim scope and bioequivalence
Section viii carve-out	Limited utility if formulation claims remain applicable
Paragraph III certification	Delayed entry until patent expiration
Paragraph IV litigation	Accelerated pathway, but substantial invalidity and injunction risk
Settlement or license	Potential earlier entry, subject to antitrust and regulatory review

The most credible design-around would require a formulation outside the asserted claim limitations while preserving FDA approval standards, stability, sterility, delivery performance, and therapeutic equivalence.

Did Allergan and Sandoz settle the case?

The appellate decision reflects an adjudicated patent dispute rather than a publicly controlling settlement outcome. No settlement terms should be treated as established from the 16-1085 opinion itself.

A later settlement, license, or consent arrangement would require separate analysis of the parties' agreement, FDA timing, entry date, authorized-generic provisions, and any restrictions on supply or marketing. Those terms are not part of the Federal Circuit merits decision.

What is the current litigation significance of Allergan v. Sandoz?

The case remains relevant in three areas.

First, it supports the use of precise ophthalmic formulation claims to protect a branded product after chemical-entity protection has weakened.

Second, it demonstrates that “about” concentration language can have enforceable scope when the specification and prosecution history support the claimed formulation.

Third, it shows that a generic applicant faces both patent and regulatory exposure when its ANDA reproduces the branded product's clinically important concentration and formulation.

The decision should be read with later developments in the broader Lumigan and Restasis patent disputes. Allergan's patent strategy across ophthalmic products included formulation, concentration, method-of-use, and continuation patents, but the validity and infringement results differed by patent family and defendant.

Key Takeaways

• Allergan v. Sandoz No. 16-1085 concerned a generic version of Lumigan 0.01%, a bimatoprost ophthalmic solution.
• The dispute centered on formulation patents, particularly the claimed approximately 0.01% concentration.
• Sandoz's Paragraph IV challenge triggered Hatch-Waxman litigation and the FDA approval stay.
• The Federal Circuit affirmed Allergan's favorable judgment.
• The case strengthened Allergan's position against generic products using the same low-concentration formulation.
• The decision did not create a composition-of-matter monopoly over bimatoprost.
• Generic applicants could still pursue design-arounds, later challenges, settlements, or entry after the relevant patent barriers expired.
• Orange Book listing enabled the statutory Hatch-Waxman litigation mechanism but did not independently establish patent validity.
• The case is distinct from later Restasis litigation involving cyclosporine ophthalmic emulsion patents.

FAQs About Allergan v. Sandoz 16-1085

What was Lumigan 0.01% used to treat?

Lumigan 0.01% was approved to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Was bimatoprost itself patented in Allergan v. Sandoz?

The litigation focused on formulation patents, not a broad patent monopoly over the bimatoprost molecule.

Could Sandoz launch a different bimatoprost concentration?

A different concentration could reduce infringement risk, but it would create separate FDA, bioequivalence, stability, efficacy, and commercial questions.

Did the Federal Circuit invalidate Allergan's Lumigan patents?

No. The Federal Circuit upheld the favorable judgment for Allergan in the appeal identified as No. 16-1085.

Does the case establish that all ophthalmic concentration patents are valid?

No. Patent validity depends on the specific claims, specification, prosecution history, prior art, and accused ANDA product.

References

1. Allergan, Inc. v. Sandoz Inc., No. 16-1085 (Fed. Cir. 2017).

2. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

3. 35 U.S.C. § 271(e)(2).

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov

5. 35 U.S.C. §§ 154, 156.